AZD0120 for Multiple Sclerosis

(ZENITH Trial)

This trial tests a new treatment called AZD0120, an experimental therapy for individuals with Multiple Sclerosis (MS), specifically targeting those with relapsing or progressive MS. The main goal is to assess the treatment's safety and understand its processing in the body. The trial divides participants into two groups: one for relapsing MS and another for progressive MS. Those who have experienced recent relapses or have not responded well to other treatments might be suitable candidates. As a Phase 1 trial, participants will be among the first to receive this treatment, aiding researchers in understanding its effects in people.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research shows that AZD0120 is in the early stages of testing, primarily to assess its safety in humans. This cell therapy targets specific proteins associated with multiple sclerosis. Although detailed information about its safety in humans is limited, the current testing phase focuses on evaluating how well participants tolerate the treatment and identifying any side effects.

AZD0120 is unique because it targets multiple sclerosis in a novel way by specifically focusing on different types of the disease, including relapsing and progressive forms. Unlike standard treatments like interferons and monoclonal antibodies, which mainly aim to reduce inflammation or modulate the immune system, AZD0120 may offer a new mechanism of action that addresses the underlying disease process. Researchers are excited because this could mean more effective management of symptoms and potentially slowing disease progression, offering hope for patients who have limited options with current therapies.

Research has shown that AZD0120, a new type of cell therapy, may help treat multiple sclerosis. Early study results suggest it works well and is safe, with no reported cases of brain swelling. This indicates the treatment might effectively target and reduce harmful cells in the body. In this trial, participants will receive AZD0120, with one group focusing on relapsing-remitting multiple sclerosis (RMS) and another on progressive multiple sclerosis (PMS). For individuals with severe relapsing-remitting multiple sclerosis (RRMS), treatments like AZD0120 have led to stable remission and significant improvement over two years. While more information about AZD0120's effects on multiple sclerosis is still being gathered, these early signs are promising.²³⁶⁷⁸